Developing STAT3 inhibitors to treat cancer by enhancing efficacy of immunotherapies and reversing drug resistance

Building on strong science and robust data to deliver real and meaningful benefits for patients


Glactone Pharma is developing novel drugs that target a key transcription factor signaling pathway for the treatment of advanced and treatment resistant cancers to improve the lives of cancer patients



2016-04-13 Glactone Pharma to participate at ACCR Annual Meeting 2016, April 16-20, in New Orleans, USA (view here)

2016-03-29 Press release: Glactone Pharma’s preferential rights issue fully subscribed (view here

2016-02-04 Press release: Glactone Pharma announces appointments to new Scientific Advisory Board (view here)

2016-01-04 Glactone Pharma to present at Biotech Showcase™ 2016, on January 13, in San Francisco, USA (view here)

2015-12-14 Press release:  Glactone Pharma is awarded financing from VINNOVA (view here)

2015-09-09 Press release: Glactone Pharma is granted a European patent (view here)

2015-07-07 Press release: Glactone Pharma innovators publish new study showing that the STAT3 inhibitor galiellalactone reduces tumor growth and metastatic spread in an animal model of prostate cancer (view here)

2015-06-01 BioWorld Today publishes article about Glactone Pharma and the potential for combining STAT3 inhibitors with  immunotherapies (view article)

2015-05-22 Press release: ASCO – Glactone Pharma demonstrates that new compound reduces immunosuppressive markers in prostate cancer cells (view here)

2015-03-10 Press release: Glactone Pharma to present data at AACR 2015 (view here)

2014-06-10 Glactone Pharma profiled in BioCentury (view article)

2014-04-23 Innovators publish new data on STAT3 inhibition in JBC

2014-01-15 Press release: PULS (english)

2014-01-15 Press release: Glactone